(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
The Tuberous Sclerosis Clinic at Cincinnati Children’s is active in many clinical, translational and basic science research studies aimed at improving care for children and adults with tuberous sclerosis. Clinical research is led by David Franz, MD, and Darcy Krueger, MD, PhD, in close collaboration with researchers in many departments at Cincinnati Children’s, the University of Cincinnati and around the world.
Studies include several human clinical trials aimed at determining the safety and effectiveness of mTOR inhibitors and other agents to treat subependymal giant cell astrocytoma (SEGA) tumors in the brain, angiomyolipomas (AMLs) in the kidneys and lymphangioleiomyomatosis (LAM) of the lungs. We are also investigating the use of these agents for the treatment of seizures, behavior problems and cognitive impairments that are frequently associated with TS. Additional projects aim to better understand how TS develops in individuals with genetic mutations in TSC1 or TSC2 and provide improved diagnostic tools and treatment approaches for TS.
> Search for research studies currently seeking participants
Learn more about the cutting-edge research being done in the Division of Neurology at Cincinnati Children's.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center